OrthoPediatrics (KIDS) Financials

$20.17 -0.19 (-0.93%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$19.97 -0.20 (-0.99%)

As of 05/30/2025 04:20 PM Eastern

Annual Income Statements for OrthoPediatrics

This table shows OrthoPediatrics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-38	-21	1.26
Consolidated Net Income / (Loss)	-38	-21	1.26
Net Income / (Loss) Continuing Operations	-38	-21	1.26
Total Pre-Tax Income	-42	-21	-3.69
Total Operating Income	-35	-27	-25
Total Gross Profit	149	111	91
Total Revenue	205	149	122
Operating Revenue	205	149	122
Total Cost of Revenue	56	37	32
Operating Cost of Revenue	56	37	32
Total Operating Expenses	184	138	116
Selling, General & Admin Expense	103	73	58
Marketing Expense	64	53	46
Research & Development Expense	11	11	8.45
Impairment Charge	1.84	0.99	3.61
Restructuring Charge	3.65	0.00	0.00
Total Other Income / (Expense), net	-6.92	5.44	22
Interest Expense	5.85	-0.20	2.42
Other Income / (Expense), net	-1.07	5.24	24
Income Tax Expense	-4.11	-0.34	-4.95
Basic Earnings per Share	($1.64)	($0.92)	$0.06
Weighted Average Basic Shares Outstanding	23.08M	22.68M	20.70M
Diluted Earnings per Share	($1.64)	($0.92)	$0.06
Weighted Average Diluted Shares Outstanding	23.08M	22.68M	20.95M
Weighted Average Basic & Diluted Shares Outstanding	24.29M	23.55M	22.99M

This table shows OrthoPediatrics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-16	-7.92	-6.03	-7.81	-6.69	-4.59	-2.89	-6.81	-7.85	19
Consolidated Net Income / (Loss)	-16	-7.92	-6.03	-7.81	-6.69	-4.59	-2.89	-6.81	-7.85	19
Net Income / (Loss) Continuing Operations	-16	-7.92	-6.03	-7.81	-6.69	-4.59	-2.89	-6.81	-7.85	19
Total Pre-Tax Income	-16	-9.14	-6.05	-10	-6.90	-3.74	-3.29	-7.38	-7.90	14
Total Operating Income	-14	-5.57	-5.67	-9.72	-8.07	-4.51	-5.59	-8.59	-8.31	-6.96
Total Gross Profit	36	40	41	32	27	31	30	24	21	26
Total Revenue	53	55	53	45	38	40	40	32	31	35
Operating Revenue	53	55	53	45	38	40	40	32	31	35
Total Cost of Revenue	17	15	12	13	11	9.02	9.53	8.03	9.77	9.06
Operating Cost of Revenue	17	15	12	13	11	9.02	9.53	8.03	9.77	9.06
Total Operating Expenses	50	46	46	42	35	35	36	32	30	33
Selling, General & Admin Expense	24	26	27	25	19	18	19	17	15	15
Marketing Expense	17	17	17	14	13	14	14	13	12	12
Research & Development Expense	2.92	2.58	2.54	3.00	2.92	2.56	2.97	2.45	2.47	2.21
Total Other Income / (Expense), net	-2.35	-3.57	-0.38	-0.61	1.16	0.77	2.30	1.21	0.41	21
Interest Expense	1.32	3.63	0.26	0.64	-0.30	0.02	0.29	-0.21	-0.06	0.71
Other Income / (Expense), net	-1.04	0.06	-0.12	0.02	0.86	0.79	2.59	1.00	-2.22	22
Income Tax Expense	-0.34	-1.22	-0.02	-2.53	-0.21	0.85	-0.40	-0.57	-0.05	-4.14
Basic Earnings per Share	($0.70)	($0.34)	($0.26)	($0.34)	($0.29)	($0.20)	($0.13)	($0.30)	($0.33)	$0.88
Weighted Average Basic Shares Outstanding	23.08M	23.17M	23.15M	22.82M	22.68M	22.76M	22.70M	22.51M	20.70M	21.15M
Diluted Earnings per Share	($0.70)	($0.34)	($0.26)	($0.34)	($0.29)	($0.20)	($0.13)	($0.30)	($0.32)	$0.87
Weighted Average Diluted Shares Outstanding	23.08M	23.17M	23.15M	22.82M	22.68M	22.76M	22.70M	22.51M	20.95M	21.30M
Weighted Average Basic & Diluted Shares Outstanding	24.29M	24.22M	24.21M	23.83M	23.55M	23.35M	23.35M	23.33M	22.99M	22.89M

This table details how cash moves in and out of OrthoPediatrics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	13	23	1.46
Net Cash From Operating Activities	-27	-27	-22
Net Cash From Continuing Operating Activities	-27	-27	-22
Net Income / (Loss) Continuing Operations	-38	-21	1.26
Consolidated Net Income / (Loss)	-38	-21	1.26
Depreciation Expense	19	17	13
Non-Cash Adjustments To Reconcile Net Income	19	13	13
Changes in Operating Assets and Liabilities, net	-28	-36	-49
Net Cash From Investing Activities	-13	42	-113
Net Cash From Continuing Investing Activities	-13	42	-113
Purchase of Property, Plant & Equipment	-14	-17	-10
Acquisitions	-23	-3.10	-40
Purchase of Investments	-26	-51	-110
Sale and/or Maturity of Investments	50	113	47
Net Cash From Financing Activities	53	7.30	136
Net Cash From Continuing Financing Activities	53	7.30	136
Repayment of Debt	-16	-0.14	-31
Issuance of Debt	74	9.42	31
Issuance of Common Equity	0.00	0.00	139
Other Financing Activities, net	-4.61	-1.98	-3.17
Effect of Exchange Rate Changes	-0.18	0.63	0.62
Cash Interest Paid	2.75	0.04	0.70

This table details how cash moves in and out of OrthoPediatrics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-7.12	22	7.33	-9.46	21	0.92	-25	26	-26	-1.28
Net Cash From Operating Activities	-3.99	-10	-6.09	-6.69	-7.54	-8.67	-4.37	-6.46	-3.34	-6.06
Net Cash From Continuing Operating Activities	-3.99	-10	-6.09	-6.69	-7.54	-8.67	-4.37	-6.46	-3.34	-6.06
Net Income / (Loss) Continuing Operations	-16	-7.92	-6.03	-7.81	-6.69	-4.59	-2.89	-6.81	-7.85	19
Consolidated Net Income / (Loss)	-16	-7.92	-6.03	-7.81	-6.69	-4.59	-2.89	-6.81	-7.85	19
Depreciation Expense	3.99	5.28	4.78	5.03	5.19	4.27	4.08	3.85	3.52	3.29
Non-Cash Adjustments To Reconcile Net Income	5.88	7.21	3.20	3.08	3.03	3.63	3.73	2.49	2.08	5.67
Changes in Operating Assets and Liabilities, net	2.21	-15	-8.04	-6.99	-9.07	-12	-9.30	-6.00	-1.10	-34
Net Cash From Investing Activities	-2.41	-27	20	-3.68	18	9.67	-18	32	-23	-104
Net Cash From Continuing Investing Activities	-2.41	-27	20	-3.68	18	9.67	-18	32	-23	-104
Purchase of Property, Plant & Equipment	0.26	-1.38	-6.68	-6.46	-3.84	-3.03	-5.62	-4.94	0.52	-1.09
Acquisitions	23	-25	-	-21	49	-4.00	-48	0.00	-	-32
Purchase of Investments	-25	-	-	-	-	-	-	-	-25	-85
Net Cash From Financing Activities	-0.54	59	-4.27	-0.57	9.39	-0.02	-2.04	-0.04	-0.04	108
Net Cash From Continuing Financing Activities	-0.54	59	-4.27	-0.57	9.39	-0.02	-2.04	-0.04	-0.04	108
Repayment of Debt	0.57	-15	-0.77	-0.57	-0.04	-0.04	-0.04	-0.04	-0.04	-31
Other Financing Activities, net	-1.11	-	-	-	-	0.02	-	-	-	0.02
Cash Interest Paid	1.37	0.62	0.54	0.22	0.01	0.02	-	0.01	0.19	0.45

This table presents OrthoPediatrics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	473	439	428
Total Current Assets	237	226	227
Cash & Equivalents	44	31	8.99
Restricted Cash	1.96	1.97	1.47
Short-Term Investments	25	49	109
Accounts Receivable	42	35	25
Inventories, net	117	106	78
Prepaid Expenses	7.02	3.75	3.97
Plant, Property, & Equipment, net	51	41	34
Total Noncurrent Assets	185	171	167
Goodwill	94	84	87
Intangible Assets	81	85	80
Other Noncurrent Operating Assets	10	2.94	0.00
Total Liabilities & Shareholders' Equity	473	439	428
Total Liabilities	119	62	49
Total Current Liabilities	34	42	31
Short-Term Debt	0.16	0.15	0.14
Accounts Payable	8.91	13	11
Current Employee Benefit Liabilities	14	11	6.74
Other Current Liabilities	11	18	13
Total Noncurrent Liabilities	85	20	18
Long-Term Debt	73	9.91	0.76
Noncurrent Deferred & Payable Income Tax Liabilities	3.38	5.48	5.95
Other Noncurrent Operating Liabilities	8.34	4.66	11
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	355	377	379
Total Preferred & Common Equity	355	377	379
Total Common Equity	355	377	379
Common Stock	601	580	561
Retained Earnings	-236	-198	-177
Accumulated Other Comprehensive Income / (Loss)	-11	-5.53	-5.40

This table presents OrthoPediatrics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	489	431	437	432	435	426	430
Total Current Assets	248	194	204	226	223	225	225
Cash & Equivalents	51	29	22	11	9.71	35	35
Restricted Cash	2.00	1.96	1.96	1.59	1.60	1.48	1.45
Short-Term Investments	25	0.00	26	72	83	73	85
Accounts Receivable	43	42	36	38	34	27	26
Inventories, net	121	116	113	101	91	85	74
Prepaid Expenses	6.49	4.50	5.06	3.98	3.64	4.01	2.75
Plant, Property, & Equipment, net	55	53	49	40	40	37	36
Total Noncurrent Assets	186	183	185	166	172	164	169
Goodwill	91	91	91	81	83	84	88
Intangible Assets	85	87	89	85	88	80	81
Other Noncurrent Operating Assets	10	6.47	4.08	0.62	0.61	-	-
Total Liabilities & Shareholders' Equity	489	431	437	432	435	426	430
Total Liabilities	118	59	67	58	55	53	47
Total Current Liabilities	35	40	46	48	44	35	29
Short-Term Debt	0.16	0.16	0.15	0.15	0.15	0.15	0.14
Accounts Payable	12	17	20	23	21	17	11
Current Employee Benefit Liabilities	13	13	9.77	8.67	8.16	6.24	6.32
Other Current Liabilities	9.60	9.80	16	17	15	12	11
Total Noncurrent Liabilities	84	20	21	10	10	18	18
Long-Term Debt	73	9.78	10	0.65	0.69	0.73	0.80
Noncurrent Deferred & Payable Income Tax Liabilities	4.03	4.74	5.20	5.49	5.56	6.02	5.46
Other Noncurrent Operating Liabilities	7.21	5.38	5.43	4.05	4.00	11	12
Total Equity & Noncontrolling Interests	371	371	371	374	380	373	383
Total Preferred & Common Equity	371	371	371	374	380	373	383
Total Common Equity	371	371	371	374	380	373	383
Common Stock	597	593	583	578	575	563	559
Retained Earnings	-219	-212	-206	-191	-186	-184	-169
Accumulated Other Comprehensive Income / (Loss)	-6.60	-10	-6.96	-12	-7.91	-6.05	-7.10

This table displays calculated financial ratios and metrics derived from OrthoPediatrics' official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	37.65%	21.62%	24.72%
EBITDA Growth	-312.07%	-134.86%	365.28%
EBIT Growth	-67.73%	-1,600.40%	91.65%
NOPAT Growth	-30.87%	-5.32%	-40.92%
Net Income Growth	-80.33%	-1,767.25%	107.74%
EPS Growth	-78.26%	-1,633.33%	107.14%
Operating Cash Flow Growth	-0.01%	-24.26%	-66.62%
Free Cash Flow Firm Growth	-20.17%	39.91%	-217.08%
Invested Capital Growth	17.09%	17.33%	51.48%
Revenue Q/Q Growth	7.94%	4.66%	5.32%
EBITDA Q/Q Growth	-114.62%	54.74%	-38.24%
EBIT Q/Q Growth	-27.96%	13.38%	-118.68%
NOPAT Q/Q Growth	-20.64%	0.90%	65.44%
Net Income Q/Q Growth	-32.97%	5.23%	-86.29%
EPS Q/Q Growth	-33.33%	3.16%	-84.21%
Operating Cash Flow Q/Q Growth	11.62%	-18.39%	-10.71%
Free Cash Flow Firm Q/Q Growth	19.14%	-34.69%	29.75%
Invested Capital Q/Q Growth	-2.36%	4.70%	-1.10%
Profitability Metrics	-	-	-
Gross Margin	72.58%	74.80%	74.14%
EBITDA Margin	-8.30%	-2.77%	9.68%
Operating Margin	-17.10%	-17.99%	-20.77%
EBIT Margin	-17.62%	-14.46%	-1.03%
Profit (Net Income) Margin	-18.47%	-14.10%	1.03%
Tax Burden Percent	90.20%	98.41%	-34.10%
Interest Burden Percent	116.22%	99.08%	291.62%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-7.41%	-6.63%	-8.24%
ROIC Less NNEP Spread (ROIC-NNEP)	30.69%	-4.28%	-30.29%
Return on Net Nonoperating Assets (RNNOA)	-2.93%	1.08%	8.66%
Return on Equity (ROE)	-10.34%	-5.55%	0.42%
Cash Return on Invested Capital (CROIC)	-23.15%	-22.58%	-49.19%
Operating Return on Assets (OROA)	-7.91%	-4.97%	-0.35%
Return on Assets (ROA)	-8.29%	-4.84%	0.34%
Return on Common Equity (ROCE)	-10.34%	-5.55%	0.42%
Return on Equity Simple (ROE_SIMPLE)	-10.67%	-5.56%	0.33%
Net Operating Profit after Tax (NOPAT)	-25	-19	-18
NOPAT Margin	-11.97%	-12.59%	-14.54%
Net Nonoperating Expense Percent (NNEP)	-38.10%	-2.35%	22.04%
Return On Investment Capital (ROIC_SIMPLE)	-5.73%	-4.84%	-4.68%
Cost of Revenue to Revenue	27.42%	25.20%	25.86%
SG&A Expenses to Revenue	50.21%	49.28%	47.35%
R&D to Revenue	5.39%	7.33%	6.91%
Operating Expenses to Revenue	89.68%	92.79%	94.91%
Earnings before Interest and Taxes (EBIT)	-36	-22	-1.27
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-17	-4.13	12
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	1.58	2.01	2.40
Price to Tangible Book Value (P/TBV)	3.13	3.64	4.29
Price to Revenue (P/Rev)	2.74	5.10	7.44
Price to Earnings (P/E)	0.00	0.00	722.96
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.14%
Enterprise Value to Invested Capital (EV/IC)	1.58	2.25	3.04
Enterprise Value to Revenue (EV/Rev)	2.75	4.62	6.47
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	66.81
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.21	0.03	0.00
Long-Term Debt to Equity	0.21	0.03	0.00
Financial Leverage	-0.10	-0.25	-0.29
Leverage Ratio	1.25	1.15	1.21
Compound Leverage Factor	1.45	1.14	3.53
Debt to Total Capital	17.10%	2.60%	0.24%
Short-Term Debt to Total Capital	0.04%	0.04%	0.04%
Long-Term Debt to Total Capital	17.06%	2.56%	0.20%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	82.90%	97.40%	99.76%
Debt to EBITDA	-4.30	-2.44	0.08
Net Debt to EBITDA	-0.14	17.51	-10.04
Long-Term Debt to EBITDA	-4.29	-2.40	0.06
Debt to NOPAT	-2.98	-0.54	-0.05
Net Debt to NOPAT	-0.09	3.86	6.69
Long-Term Debt to NOPAT	-2.98	-0.53	-0.04
Altman Z-Score	2.84	7.43	11.37
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	6.98	5.44	7.34
Quick Ratio	3.27	2.76	4.64
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-77	-64	-106
Operating Cash Flow to CapEx	-189.64%	-155.22%	-216.99%
Free Cash Flow to Firm to Interest Expense	-13.09	0.00	-43.76
Operating Cash Flow to Interest Expense	-4.62	0.00	-8.98
Operating Cash Flow Less CapEx to Interest Expense	-7.06	0.00	-13.12
Efficiency Ratios	-	-	-
Asset Turnover	0.45	0.34	0.33
Accounts Receivable Turnover	5.32	5.01	5.72
Inventory Turnover	0.50	0.41	0.47
Fixed Asset Turnover	4.47	3.95	3.89
Accounts Payable Turnover	5.21	3.15	3.09
Days Sales Outstanding (DSO)	68.62	72.91	63.79
Days Inventory Outstanding (DIO)	724.60	896.18	783.34
Days Payable Outstanding (DPO)	70.09	115.89	118.14
Cash Conversion Cycle (CCC)	723.13	853.20	728.99
Capital & Investment Metrics	-	-	-
Invested Capital	357	305	260
Invested Capital Turnover	0.62	0.53	0.57
Increase / (Decrease) in Invested Capital	52	45	88
Enterprise Value (EV)	564	687	791
Market Capitalization	561	759	909
Book Value per Share	$14.64	$16.14	$16.54
Tangible Book Value per Share	$7.41	$8.94	$9.26
Total Capital	428	387	380
Total Debt	73	10	0.91
Total Long-Term Debt	73	9.91	0.76
Net Debt	2.33	-72	-119
Capital Expenditures (CapEx)	14	17	10
Debt-free, Cash-free Net Working Capital (DFCFNWC)	133	103	76
Debt-free Net Working Capital (DFNWC)	203	185	196
Net Working Capital (NWC)	203	185	196
Net Nonoperating Expense (NNE)	13	2.25	-19
Net Nonoperating Obligations (NNO)	2.33	-72	-119
Total Depreciation and Amortization (D&A)	19	17	13
Debt-free, Cash-free Net Working Capital to Revenue	64.76%	69.05%	62.34%
Debt-free Net Working Capital to Revenue	99.34%	124.37%	160.27%
Net Working Capital to Revenue	99.26%	124.27%	160.15%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($1.64)	($0.92)	$0.06
Adjusted Weighted Average Basic Shares Outstanding	23.08M	22.68M	20.70M
Adjusted Diluted Earnings per Share	($1.64)	($0.92)	$0.06
Adjusted Weighted Average Diluted Shares Outstanding	23.08M	22.68M	20.95M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	24.29M	23.55M	22.99M
Normalized Net Operating Profit after Tax (NOPAT)	-21	-18	-15
Normalized NOPAT Margin	-10.09%	-12.13%	-12.47%
Pre Tax Income Margin	-20.48%	-14.33%	-3.02%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-6.17	0.00	-0.52
NOPAT to Interest Expense	-4.19	0.00	-7.33
EBIT Less CapEx to Interest Expense	-8.60	0.00	-4.66
NOPAT Less CapEx to Interest Expense	-6.63	0.00	-11.47
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from OrthoPediatrics' official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	40.02%	36.53%	33.48%	41.46%	21.36%	14.37%	20.14%	34.89%	24.91%	39.36%
EBITDA Growth	-449.63%	-140.62%	-192.64%	-24.83%	71.19%	-97.01%	-71.17%	-12.71%	-2,290.00%	2,912.08%
EBIT Growth	-109.41%	-47.89%	-93.32%	-27.79%	31.55%	-124.64%	-780.23%	-20.84%	-322.81%	547.26%
NOPAT Growth	-74.25%	-23.47%	-1.43%	-13.18%	2.92%	64.80%	-49.24%	-34.53%	-49.42%	-251.43%
Net Income Growth	-140.16%	-72.49%	-108.91%	-14.68%	14.74%	-124.76%	-766.67%	25.21%	-11,000.00%	943.83%
EPS Growth	-141.38%	-70.00%	-100.00%	-13.33%	9.38%	-122.99%	-550.00%	36.17%	0.00%	890.91%
Operating Cash Flow Growth	47.14%	-18.57%	-39.31%	-3.54%	-125.77%	-43.10%	46.47%	-53.94%	-170.53%	-546.53%
Free Cash Flow Firm Growth	-22.24%	-147.95%	18.73%	27.67%	46.17%	70.89%	-55.37%	-250.61%	-280.57%	-633.48%
Invested Capital Growth	17.09%	25.56%	22.34%	25.06%	17.33%	10.82%	38.56%	56.08%	51.48%	61.02%
Revenue Q/Q Growth	-3.49%	3.35%	18.16%	18.80%	-5.90%	1.04%	25.23%	1.92%	-11.32%	6.14%
EBITDA Q/Q Growth	-4,876.23%	77.86%	78.44%	-131.35%	-467.76%	-49.49%	129.05%	46.60%	-138.11%	387.70%
EBIT Q/Q Growth	-174.21%	4.89%	40.34%	-34.60%	-93.66%	-24.32%	60.57%	27.91%	-169.70%	3,332.73%
NOPAT Q/Q Growth	-152.52%	1.76%	41.73%	-20.54%	-78.93%	19.30%	34.98%	-3.39%	35.12%	-242.14%
Net Income Q/Q Growth	-102.92%	-31.35%	22.75%	-16.65%	-45.74%	-59.08%	57.60%	13.28%	-142.33%	5,667.27%
EPS Q/Q Growth	-105.88%	-30.77%	23.53%	-17.24%	-45.00%	-53.85%	56.67%	6.25%	-136.78%	4,450.00%
Operating Cash Flow Q/Q Growth	61.21%	-68.73%	8.94%	11.31%	12.99%	-98.24%	32.32%	-93.39%	44.85%	25.85%
Free Cash Flow Firm Q/Q Growth	20.92%	-15.26%	7.15%	-44.45%	-60.40%	62.22%	17.36%	-7.50%	13.27%	-101.66%
Invested Capital Q/Q Growth	-2.36%	4.34%	5.78%	8.65%	4.70%	1.66%	8.14%	1.93%	-1.10%	27.10%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	67.53%	73.41%	77.27%	72.00%	71.02%	77.44%	75.90%	74.59%	68.48%	74.07%
EBITDA Margin	-21.07%	-0.41%	-1.91%	-10.45%	-5.37%	1.37%	2.75%	-11.85%	-22.61%	52.62%
Operating Margin	-26.69%	-10.20%	-10.73%	-21.76%	-21.44%	-11.28%	-14.12%	-27.20%	-26.81%	-19.92%
EBIT Margin	-28.65%	-10.08%	-10.96%	-21.71%	-19.16%	-9.31%	-7.57%	-24.03%	-33.97%	43.22%
Profit (Net Income) Margin	-30.51%	-14.51%	-11.42%	-17.47%	-17.79%	-11.49%	-7.30%	-21.55%	-25.32%	53.04%
Tax Burden Percent	97.93%	86.67%	99.70%	75.51%	96.93%	122.69%	87.80%	92.22%	99.39%	128.78%
Interest Burden Percent	108.74%	166.04%	104.51%	106.57%	95.80%	100.56%	109.82%	97.23%	75.00%	95.31%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-28.78%
Return on Invested Capital (ROIC)	-11.56%	-4.12%	-4.13%	-8.27%	-7.91%	-4.05%	-5.50%	-11.43%	-10.64%	-13.99%
ROIC Less NNEP Spread (ROIC-NNEP)	6.27%	4.96%	-0.54%	-6.92%	-6.82%	-2.64%	-7.29%	-10.40%	-8.29%	-44.78%
Return on Net Nonoperating Assets (RNNOA)	-0.60%	-0.59%	0.08%	1.37%	1.72%	0.71%	1.37%	2.72%	2.37%	13.23%
Return on Equity (ROE)	-12.16%	-4.71%	-4.05%	-6.90%	-6.19%	-3.34%	-4.12%	-8.71%	-8.27%	-0.75%
Cash Return on Invested Capital (CROIC)	-23.15%	-28.85%	-26.24%	-28.82%	-22.58%	-17.09%	-40.69%	-52.69%	-49.19%	-70.92%
Operating Return on Assets (OROA)	-12.86%	-4.15%	-4.43%	-8.14%	-6.58%	-3.07%	-2.71%	-8.62%	-11.35%	13.68%
Return on Assets (ROA)	-13.70%	-5.97%	-4.62%	-6.55%	-6.11%	-3.78%	-2.61%	-7.73%	-8.46%	16.79%
Return on Common Equity (ROCE)	-12.16%	-4.71%	-4.05%	-6.90%	-6.19%	-3.34%	-4.12%	-8.71%	-8.27%	-0.75%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-7.67%	-6.76%	-5.93%	0.00%	-5.91%	0.26%	0.95%	0.00%	2.39%
Net Operating Profit after Tax (NOPAT)	-9.84	-3.90	-3.97	-6.81	-5.65	-3.16	-3.91	-6.01	-5.82	-8.96
NOPAT Margin	-18.68%	-7.14%	-7.51%	-15.23%	-15.01%	-7.89%	-9.88%	-19.04%	-18.77%	-25.65%
Net Nonoperating Expense Percent (NNEP)	-17.83%	-9.08%	-3.59%	-1.35%	-1.09%	-1.41%	1.79%	-1.03%	-2.35%	30.80%
Return On Investment Capital (ROIC_SIMPLE)	-2.30%	-	-	-	-1.46%	-	-	-	-1.53%	-
Cost of Revenue to Revenue	32.47%	26.59%	22.73%	28.00%	28.98%	22.56%	24.10%	25.41%	31.52%	25.93%
SG&A Expenses to Revenue	46.39%	48.19%	51.76%	55.34%	50.67%	44.96%	48.31%	54.31%	48.64%	43.25%
R&D to Revenue	5.54%	4.72%	4.82%	6.71%	7.77%	6.41%	7.50%	7.74%	7.98%	6.31%
Operating Expenses to Revenue	94.21%	83.61%	88.00%	93.76%	92.47%	88.71%	90.02%	101.79%	95.29%	93.99%
Earnings before Interest and Taxes (EBIT)	-15	-5.50	-5.79	-9.70	-7.21	-3.72	-2.99	-7.59	-11	15
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-11	-0.22	-1.01	-4.67	-2.02	0.55	1.09	-3.74	-7.01	18
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.58	1.77	1.85	1.85	2.01	2.00	2.69	2.73	2.40	2.44
Price to Tangible Book Value (P/TBV)	3.13	3.37	3.53	3.62	3.64	3.58	4.89	4.88	4.29	4.37
Price to Revenue (P/Rev)	2.74	3.46	3.91	4.24	5.10	5.26	7.46	7.81	7.44	8.06
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	1,023.92	286.71	722.96	101.94
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.10%	0.35%	0.14%	0.98%
Enterprise Value to Invested Capital (EV/IC)	1.58	1.78	1.90	1.95	2.25	2.28	3.24	3.44	3.04	3.10
Enterprise Value to Revenue (EV/Rev)	2.75	3.43	3.79	4.00	4.62	4.67	6.78	6.98	6.47	7.02
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	106.43	79.74	66.81	42.53
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	120.33
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.21	0.20	0.03	0.03	0.03	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.21	0.20	0.03	0.03	0.03	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.10	-0.12	-0.15	-0.20	-0.25	-0.27	-0.19	-0.26	-0.29	-0.30
Leverage Ratio	1.25	1.24	1.15	1.16	1.15	1.14	1.26	1.24	1.21	1.21
Compound Leverage Factor	1.36	2.05	1.20	1.24	1.10	1.14	1.38	1.20	0.91	1.16
Debt to Total Capital	17.10%	16.38%	2.61%	2.71%	2.60%	0.21%	0.22%	0.23%	0.24%	0.25%
Short-Term Debt to Total Capital	0.04%	0.04%	0.04%	0.04%	0.04%	0.04%	0.04%	0.04%	0.04%	0.04%
Long-Term Debt to Total Capital	17.06%	16.35%	2.57%	2.67%	2.56%	0.17%	0.18%	0.19%	0.20%	0.21%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	82.90%	83.62%	97.39%	97.29%	97.40%	99.79%	99.78%	99.77%	99.76%	99.75%
Debt to EBITDA	-4.30	-9.18	-1.39	-2.04	-2.44	-0.09	0.10	0.08	0.08	0.05
Net Debt to EBITDA	-0.14	0.68	2.93	7.80	17.51	9.13	-10.76	-9.49	-10.04	-6.30
Long-Term Debt to EBITDA	-4.29	-9.16	-1.37	-2.01	-2.40	-0.07	0.08	0.06	0.06	0.04
Debt to NOPAT	-2.98	-3.58	-0.51	-0.53	-0.54	-0.04	-0.04	-0.05	-0.05	-0.02
Net Debt to NOPAT	-0.09	0.27	1.07	2.02	3.86	4.40	4.56	5.61	6.69	2.35
Long-Term Debt to NOPAT	-2.98	-3.57	-0.50	-0.52	-0.53	-0.03	-0.03	-0.04	-0.04	-0.02
Altman Z-Score	2.98	3.57	7.02	6.26	7.54	7.89	11.44	11.68	11.29	12.40
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	6.98	7.17	4.90	4.45	5.44	4.72	5.04	6.39	7.34	7.81
Quick Ratio	3.27	3.43	1.79	1.83	2.76	2.51	2.87	3.82	4.64	5.09
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-62	-78	-68	-73	-51	-32	-84	-101	-94	-109
Operating Cash Flow to CapEx	0.00%	-744.32%	-91.14%	-103.56%	-196.64%	-286.58%	-77.77%	-130.79%	0.00%	-556.29%
Free Cash Flow to Firm to Interest Expense	-46.95	-21.55	-260.31	-114.87	0.00	-1,503.93	-284.36	0.00	0.00	-153.26
Operating Cash Flow to Interest Expense	-3.02	-2.83	-23.34	-10.50	0.00	-412.81	-14.87	0.00	0.00	-8.56
Operating Cash Flow Less CapEx to Interest Expense	-2.82	-3.21	-48.95	-20.64	0.00	-556.86	-34.00	0.00	0.00	-10.09
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.45	0.41	0.40	0.37	0.34	0.33	0.36	0.36	0.33	0.32
Accounts Receivable Turnover	5.32	4.71	4.61	5.13	5.01	4.45	4.63	5.83	5.72	5.24
Inventory Turnover	0.50	0.45	0.43	0.42	0.41	0.42	0.46	0.47	0.47	0.44
Fixed Asset Turnover	4.47	3.99	3.74	3.78	3.95	3.71	3.58	3.84	3.89	3.57
Accounts Payable Turnover	5.21	2.92	2.35	2.30	3.15	2.17	2.05	2.23	3.09	2.88
Days Sales Outstanding (DSO)	68.62	77.43	79.10	71.17	72.91	81.97	78.92	62.60	63.79	69.68
Days Inventory Outstanding (DIO)	724.60	809.55	851.67	859.42	896.18	876.47	794.69	781.28	783.34	826.61
Days Payable Outstanding (DPO)	70.09	125.14	155.64	158.43	115.89	168.03	177.93	163.96	118.14	126.72
Cash Conversion Cycle (CCC)	723.13	761.84	775.12	772.17	853.20	790.41	695.67	679.91	728.99	769.56
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	357	366	350	331	305	291	286	265	260	263
Invested Capital Turnover	0.62	0.58	0.55	0.54	0.53	0.51	0.56	0.60	0.57	0.55
Increase / (Decrease) in Invested Capital	52	74	64	66	45	28	80	95	88	100
Enterprise Value (EV)	564	651	664	647	687	664	929	910	791	815
Market Capitalization	561	656	685	687	759	747	1,023	1,018	909	936
Book Value per Share	$14.64	$15.32	$15.58	$15.74	$16.14	$16.03	$16.30	$16.23	$16.54	$18.90
Tangible Book Value per Share	$7.41	$8.05	$8.15	$8.07	$8.94	$8.95	$8.98	$9.08	$9.26	$10.56
Total Capital	428	444	381	381	387	375	381	374	380	384
Total Debt	73	73	9.94	10	10	0.80	0.84	0.87	0.91	0.94
Total Long-Term Debt	73	73	9.78	10	9.91	0.65	0.69	0.73	0.76	0.80
Net Debt	2.33	-5.39	-21	-39	-72	-83	-94	-108	-119	-121
Capital Expenditures (CapEx)	-0.26	1.38	6.68	6.46	3.84	3.03	5.62	4.94	-0.52	1.09
Debt-free, Cash-free Net Working Capital (DFCFNWC)	133	136	123	108	103	94	84	81	76	74
Debt-free Net Working Capital (DFNWC)	203	214	154	158	185	178	179	190	196	196
Net Working Capital (NWC)	203	214	154	158	185	178	179	190	196	196
Net Nonoperating Expense (NNE)	6.23	4.02	2.06	1.00	1.04	1.44	-1.02	0.79	2.03	-28
Net Nonoperating Obligations (NNO)	2.33	-5.39	-21	-39	-72	-83	-94	-108	-119	-121
Total Depreciation and Amortization (D&A)	3.99	5.28	4.78	5.03	5.19	4.27	4.08	3.85	3.52	3.29
Debt-free, Cash-free Net Working Capital to Revenue	64.76%	71.59%	70.53%	66.96%	69.05%	66.41%	61.50%	61.85%	62.34%	64.06%
Debt-free Net Working Capital to Revenue	99.34%	112.74%	88.18%	97.67%	124.37%	125.53%	130.64%	145.56%	160.27%	168.77%
Net Working Capital to Revenue	99.26%	112.66%	88.09%	97.58%	124.27%	125.42%	130.53%	145.45%	160.15%	168.65%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.70)	($0.34)	($0.26)	($0.34)	($0.29)	($0.20)	($0.13)	($0.30)	($0.33)	$0.88
Adjusted Weighted Average Basic Shares Outstanding	23.08M	23.17M	23.15M	22.82M	22.68M	22.76M	22.70M	22.51M	20.70M	21.15M
Adjusted Diluted Earnings per Share	($0.70)	($0.34)	($0.26)	($0.34)	($0.29)	($0.20)	($0.13)	($0.30)	($0.32)	$0.87
Adjusted Weighted Average Diluted Shares Outstanding	23.08M	23.17M	23.15M	22.82M	22.68M	22.76M	22.70M	22.51M	20.95M	21.30M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	24.29M	24.22M	24.21M	23.83M	23.55M	23.35M	23.35M	23.33M	22.99M	22.89M
Normalized Net Operating Profit after Tax (NOPAT)	-9.84	-3.90	-3.97	-6.81	-5.65	-2.47	-3.91	-6.01	-5.82	-2.35
Normalized NOPAT Margin	-18.68%	-7.14%	-7.51%	-15.23%	-15.01%	-6.17%	-9.88%	-19.04%	-18.77%	-6.71%
Pre Tax Income Margin	-31.16%	-16.74%	-11.45%	-23.13%	-18.35%	-9.36%	-8.31%	-23.36%	-25.48%	41.19%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-11.44	-1.51	-22.17	-15.23	0.00	-177.19	-10.18	0.00	0.00	21.33
NOPAT to Interest Expense	-7.46	-1.07	-15.20	-10.68	0.00	-150.27	-13.30	0.00	0.00	-12.66
EBIT Less CapEx to Interest Expense	-11.24	-1.89	-47.78	-25.37	0.00	-321.24	-29.31	0.00	0.00	19.80
NOPAT Less CapEx to Interest Expense	-7.26	-1.45	-40.81	-20.83	0.00	-294.31	-32.43	0.00	0.00	-14.20
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About OrthoPediatrics' Financials

When does OrthoPediatrics's fiscal year end?

According to the most recent income statement we have on file, OrthoPediatrics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has OrthoPediatrics' net income changed over the last 2 years?

OrthoPediatrics' net income appears to be on an upward trend, with a most recent value of -$37.82 million in 2024, falling from $1.26 million in 2022. The previous period was -$20.97 million in 2023. Find out what analysts predict for OrthoPediatrics in the coming months.

What is OrthoPediatrics's operating income?

OrthoPediatrics's total operating income in 2024 was -$35.01 million, based on the following breakdown:

Total Gross Profit: $148.60 million
Total Operating Expenses: $183.61 million

How has OrthoPediatrics revenue changed over the last 2 years?

Over the last 2 years, OrthoPediatrics' total revenue changed from $122.29 million in 2022 to $204.73 million in 2024, a change of 67.4%.

How much debt does OrthoPediatrics have?

OrthoPediatrics' total liabilities were at $118.64 million at the end of 2024, a 92.2% increase from 2023, and a 141.7% increase since 2022.

How much cash does OrthoPediatrics have?

In the past 2 years, OrthoPediatrics' cash and equivalents has ranged from $8.99 million in 2022 to $43.82 million in 2024, and is currently $43.82 million as of their latest financial filing in 2024.

How has OrthoPediatrics' book value per share changed over the last 2 years?

Over the last 2 years, OrthoPediatrics' book value per share changed from 16.54 in 2022 to 14.64 in 2024, a change of -11.5%.

Related Companies

This page (NASDAQ:KIDS) was last updated on 5/31/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OrthoPediatrics (KIDS) Financials

Frequently Asked Questions About OrthoPediatrics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

OrthoPediatrics (KIDS) Financials

Annual Income Statements for OrthoPediatrics

Quarterly Income Statements for OrthoPediatrics

Annual Cash Flow Statements for OrthoPediatrics

Quarterly Cash Flow Statements for OrthoPediatrics

Annual Balance Sheets for OrthoPediatrics

Quarterly Balance Sheets for OrthoPediatrics

Annual Metrics And Ratios for OrthoPediatrics

Quarterly Metrics And Ratios for OrthoPediatrics

Frequently Asked Questions About OrthoPediatrics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools